Filter posts

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Boosting Investment in Biotech

The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase …

Biotech IPO Window - Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue …

Want a less abundant and more expensive food supply? Rally against biotech

As millions of Americans struggle during these tough economic times, one thing we don’t have …

Biotechnology Industry Initiative to Improve U.S. Science Education

By Bianca Blanks, Biotechnology Institute Industry responds to President’s “Educate to Innovate” campaign with “Scientists …

The Burrill Report: Pushing Policies in a Changed Washington

The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the …

State Deficits to Shrink & Taxes Drop – Good News for Biotech

Forecasters at the National Conference of State Legislatures’ 2011 Legislative Summit expect a dramatic reduction …

Fall Preview: Business Development Events

Now that the Business Forum and International Convention are behind us, our Business Development department …

Raising the Stakes in Biotech

Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The …